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Abstract: Antimicrobial peptides (AMPs) represent a vast array of molecules produced by virtually
all living organisms as natural barriers against infection. Among AMP sources, an interesting class
regards the food-derived bioactive agents. The whey protein lactoferrin (Lf) is an iron-binding
glycoprotein that plays a significant role in the innate immune system, and is considered as an
important host defense molecule. In search for novel antimicrobial agents, Lf offers a new source
with potential pharmaceutical applications. The Lf-derived peptides Lf(1–11), lactoferricin (Lfcin)
and lactoferrampin exhibit interesting and more potent antimicrobial actions than intact protein.
Particularly, Lfcin has demonstrated strong antibacterial, anti-fungal and antiparasitic activity
with promising applications both in human and veterinary diseases (from ocular infections to
osteo-articular, gastrointestinal and dermatological diseases).
Keywords: antimicrobial peptides; lactoferricin; milk proteins; food safety
1. Introduction
Antimicrobial peptides (AMPs) represent a vast array of molecules produced by virtually all
living organisms as a natural barrier against infection. They are a primitive defence mechanism
found in a wide range of eukaryotic organisms, throughout the taxonomic scale, including mammals,
invertebrates and plants [1–4]. AMPs exhibit a broad range of activities against Gram-negative and
Gram-positive bacteria, fungi, viruses, and parasites. To date, 2645 AMPs from various sources have
been listed in “The Antimicrobial Peptide Database” [5], a database dedicated to natural AMPs.
This rich source of antimicrobial agents has aroused growing interest, especially in the light of the
decreasing effectiveness of antibiotics not only against severe infections, but also in treating common
infectious diseases. Resistance to antibiotics has become a threat to global public health and is driving
novel research into the development of new antimicrobial agents [6]. Innovation is thus needed not
only for the development of new antibiotics (where, for example, the worldwide pipeline for new
antibiotic classes active against highly resistant Gram-negative bacteria is almost dry) but also for
combination therapies. By targeting different mechanisms of resistance simultaneously, combination
therapy might help slow the emergence of resistance [7]. Moreover it has been strongly suggested that
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any synergy between these drugs and the immune response should be exploited in the treatment of
bacterial infections [8].
Among AMP sources, an interesting class are the food-derived bioactive agents [9]. These
AMP peptides together with other bioactive peptides are hidden inside food proteins (mainly milk
proteins) and can be decrypted by proteolytic activity [10]. Dairy proteins, protein hydrolysates, and
fermented dairy products have been shown to possess a wide spectrum of pharmacological activities:
opioid, immunomodulatory, antimicrobial and antiviral, antithrombotic, growth-stimulating, and
antihypertensive properties [11,12]. The class of AMP is particularly attracting and the “generally
recognized as safe” (GRAS) status of food satisfies both consumers and industry. Research in the
last twenty years has discovered several proteins and related peptides with interesting antimicrobial
properties: milk proteins, such as β-lactoglobulin or α-lactalbumin and particularly lactoferrin (Lf)
contain AMPs which have potential applications as pharmaceutical products [13]. The wealth of this
research area is testified by specific conferences (e.g., XII International Conference on Lactoferrin) and
a database named MilkAMP that contains all the physicochemical and microbiological characteristics
of identified antimicrobial dairy peptides [14].
Recently, reports have demonstrated that the increased spectrum of activity of Lf and related
peptides is larger than expected. Antiviral [12,15–17] and antiprotozoal activities [18] as well as tumor
inhibition [19,20] and potent anti-inflammatory, anti-catabolic, and anti-oxidative effects [21] have
been described. This article reviews the development of research on Lf-derived AMPs of bovine and
human origin, and their applications, mainly as antimicrobial agents, for use by several administration
routes and at different sites. Future prospects of lactoferrin-derived AMP will be also discussed.
2. Lactoferrin: Distribution in Body Fluids and Clinical Efficacy
The whey protein lactoferrin (Lf) is an 80 KDa iron-binding glycoprotein that plays a significant
role in the innate immune system, and is considered to be an important host defense molecule. A wide
range of physiological functions such as antiviral, [22] antimicrobial, [23] antifungal, anti-parasitic [24],
immunomodulatory [25] and antioxidant activities have been identified [26,27]. In humans, Lf is
one of the major proteins in all exocrine secretions, such as colostrum (where Lf is found at the
highest concentration, i.e., 8 mg/mL), milk, tears, saliva, seminal and gastrointestinal fluids, nasal
and bronchial mucosa, and plasma (0.2 µg/mL). Breast milk is the main source of Lf found in the
gut of infants, and accounts for the initiation, development, and/or composition of the neonatal gut
microbiota. Lf is also stored in the secondary granules of polymorphonuclear leukocytes and it has
been reported that Lf regulates multiple signalling pathways to impart cytotoxic effects on cancer
cell [19].
With regard to its antimicrobial effects, human Lf exhibits a very effective response against a
wide range of bacteria, including species of Streptococcus, Salmonella, Shigella, Staphylococcus, and
Enterobacter [28]. There is a vast literature describing the in vitro efficacy and animal-model benefits
of Lf. The principal clinical results are reported below.
One of the first applications of Lf in humans was in infant formula, and this has been the
object of systematic and critical reviews [29,30]. The majority of studies have shown Lf to be safe in
preterm/term new-born, and in older infants; in these children, protection against enteric and neonatal
infections are the most likely biologically relevant activities of Lf. Several clinical trials are currently
ongoing (data from www.clinicaltrials.gov).
Lf was also administered in a trial concerning Giardia lamblia infection; this is among the most
common protozoan infection of the human intestine causing severe diarrhoea. A cohort of children
with Giardia infection fed Lf showed a lower prevalence of colonization and better growth as compared
to unfed children [31].
Lactoferrin, naturally present in the saliva, is associated with host defense against oral pathogens.
The clinical usefulness of bovine Lf (bLf) combined with proteolytic enzymes to treat oral candidiasis or
dry mouth has been examined [32,33] and a mucoadhesive tablet containing Lf has been developed [34].
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Wakabayashi et al. evaluated the in vitro effects of Lf-related agents on the growth and biofilm formation
of two periodontopathic bacteria, Porphyromonas gingivalis and Prevotella intermedia, which reside as
biofilms in the subgingival plaque [35]. bLf used in combination with four antibiotics reduced the
amount of a preformed biofilm of P. gingivalis compared with the reduction achieved with antibiotics
alone. Improved liposomal formulations of Lf and lactoperoxidase significantly reduced the caries
incidence in rat models [36]. These results demonstrate the potential usefulness of Lf for the prevention
and treatment of periodontal diseases and as adjunct therapy in such diseases.
Recently, Lf analysis was used as a sensitive assay for detecting the degree of periodontal
inflammation and oxidative stress, and for monitoring the effects of periodontal therapy as well [37].
The Lf level was higher in the periodontitis group of patients compared to the healthy group, and
the measured level decreased in the former group after periodontal therapy. Higher Lf levels were
associated with higher values of clinical parameters (such as gingival index, plaque index, probing
pocket depth, clinical attachment level) both before and after therapy. This overall research indicates
that Lf plays an important role during periodontal disease, and crevicular Lf quantification could be a
marker for detecting periodontal inflammation, oxidative stress, and monitoring periodontal therapy.
The role of fermented milk and whey proteins in controlled clinical trials regarding Helicobacter pylori
infections was recently reviewed by Sachdeva [38]. Although the available evidence suggests that bLf
is beneficial for H. pylori eradication (Recommendation Grade-A), unlike AMP derived from Lf [39],
the extent of the documented benefit is small, and deserves further exploration. Other clinical trials
on Lf are related to: (i) the prevention of hospital-acquired infections; (ii) the treatment of cystic
fibrosis [40] in combination with hypothiocyanite; (iii) clinical efficacy against the common cold in
combination with the IgG-rich fraction of whey proteins [41].
Regarding potential Lf side effects, advanced clinical trials, including the treatment for H. pylori
infection [42], iron deficiency anemia in pregnant women [43] and new-born sepsis [44] did not report
any significant adverse effects or intolerance.
A number of functional peptides are produced from Lf by the action of proteolytic enzymes,
and many Lf-derived antimicrobial peptides have been isolated and characterized (Figure 1); three
have been studied in some detail [45]. They originate from the N-lobe of Lf, and their antimicrobial
activity is chiefly linked to hydrophobicity, cationic charge, and helical conformation, which render
these peptides amphiphilic molecules. Most of them cause membrane depolarization (like the
antibiotics colistin and polimixin B) [46]. However, complex mechanisms, such as inhibition of
the synthesis of macromolecules [47], and synergic action with host innate immunity compounds were
also described [48]. The three peptides are Lf(1–11), lactoferricin (Lfcin) and lactoferrampin (LFampin);
the alphabetic letter indicates the species of origin, e.g., (b) for bovine and (h) for human [49].
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3. Lf Derived Peptides: Lf(1–11)
Lf(1–11) is the oligopeptide including the first eleven aminoacid residues of the Lf molecule
(Figure 2). The sequence comparison of Lf(1–11) from six mammalian species (Table 1) shows that
some important features such as the highly cationic nature of the peptide is maintained (pI > 11,
ranging from 11.70 (bovine) to 12.5 (human)) and the hydrophobic residues valine and tryptophan
V6 and W8 are conserved in all species. Investigation of the structural and dynamic properties in
water and membrane-mimicking solvents show that hLf(1–11) effectively interacts with the membrane,
whereas the control peptide (a scrambled analogue) did not show such conformation [40].
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For the different amino acids, the colours indicate: blue = positively charged (R, K, H); black = negatively
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3.1. In Vitro Antibacterial and Anti-Fungal Activity of Lf(1–11)
In a recent study, hLf(1–11) (milkAMP database id = LFH0004) was investigated for its ability
to treat infections caused by multi-drug-resistant bacteria. The results showed that hLf(1–11) was
active against various Gram positive bacteria such as Staphylococcus spp. (including MRSA), and
Streptococcus mitis (MIC values ranged from 1.6 to 6.3 µg/mL) as well as Gram-negative bacteria:
Acinetobacter baumannii, Pseudomonas spp., Klebsiella spp. and E. coli (MIC values 6.3 to 12.5 µg/mL).
As far as Yeasts are concerned in Candida spp. (MIC > 12.5 µg/mL) were found [49].
This peptide’s anti-fungal action mechanism appears to involve a particular sequence of events.
The peptide interacts with structural elements of the plasma membrane of the blastoconidia, and
is taken up in an energy-dependent manner. Inside the cell it triggers the energized mitochondria
to synthesize and secrete ATP, and the peptide is released extracellularly, where it interacts with
surface ATP binding sites, resulting in pore formation. These events induce progression towards cell
death, possibly involving mitochondria [50]. Another study demonstrated the involvement of fungal
endogenous thiols and reactive oxygen species (ROS) in the candidacidal activity exerted by hLf(1–11).
In this study, hLf(1–11) caused a decrease in the internal thiol levels of Candida albicans by 20% and an
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increase in the level of its production of ROS in a dose-dependent manner; a correlation between ROS
production and candidacidal activity was also found [51].
Little has been reported concerning the synergistic effects of hLf(1–11) with antibiotics. It has
been observed that Lf or hLf(1–11), added at sub-inhibitory concentrations to antifungal agents
such as clotrimazole, ketoconazole, fluconazole, or itraconazole, reduces the minimum inhibitory
concentrations of these agents against Candida species [52]. The peptide was highly active against
fluconazole-resistant Candida albicans at non-candidacidal concentrations, acted synergistically with
fluconazole against this yeast and a fluconazole-sensitive C. albicans strain, as well as against C. glabrata,
C. krusei, C. parapsilosis and C. tropicalis. When these yeasts were exposed to hLf(1–11) for five minutes
and then incubated with fluconazole, they were effectively killed, while no candidacidal activity was
observed when they were incubated first with fluconazole and then exposed to the peptide: this shows
that the candidacidal activity is initiated by the peptide, whereas fluconazole is only required during
the effector phase [53].
3.2. Main in Vivo Results in Human and Animal Models
hLf(1–11) showed activity with 2.5 log reduction against an antibiotic-resistant S. aureus strain
(at 12 µM) [54]; it retained its activity when bound to bone cements used clinically [55]. In rabbit
model trials using cement containing hLf(1–11), two studies [56,57] revealed a significant reduction
of bone-injected S. aureus ATCC 10832 bacteria or S. aureus (W234) compared with the control
group. The results clearly showed that hLf(1–11) has the ability to reduce osteomyelitis, with
microbiological results similar to those of gentamicin [57]. In an earlier study, the intravenous injection
of hLf(1–11) at 0.1 or 1 nmol successfully reduced murine muscle infections (1 ˆ 107 CFU) caused by
the methicillin-resistant S. aureus strain 2141 (MRSA), Klebsiella pneumoniae ATCC 43816 [54], S. aureus
25923 [58], and various multidrug-resistant Acinetobacter baumannii [59].
In an interesting report using labelled hLf(1–11), the administration routes of the peptide
were compared (oral, i.p., i.v. and s.c.) on mice infected with multidrug resistant S. aureus [60].
A dose-dependent effect was observed with increasing i.v. doses, from 0.04 to 40 mg/kg of body
weight, with maximal reduction of viable bacteria in infected thigh muscle of 4 log CFU/g of tissue
compared with control. hLf(1–11) was rapidly removed from the circulation after i.v. administration
(blood half-life t = 5–10 min) through the kidneys. This administration route produced the highest
concentration in muscle tissue (0.9% ID/g). Removal was slower for orally-administered peptide,
and 38% ID/g of the radioactivity still remained in the stomach and 40% in the intestine 2 h after
administration [60].
Following the promising in vitro antifungal results, in vivo activity of hLf(1–11) against
fluconazole-resistant C. albicans was investigated using neutrocytopenic mice infected with C. albicans
Y01-19. A reduction of clinical signs and symptoms of the infection was observed at a dose 0.4 µg/kg
of body weight, much lower than that found in in vitro experiments [49]. The most likely explanation
for the levelling off of the antifungal effects of hLf(1–11) is that the peptide induces multiple processes
that contribute differently to its antifungal activity. Furthermore, administering hLf(1–11) at up to
10,000 times the therapeutic dose produced no significant adverse or toxic effects, and consequently
the therapeutic window of the peptide is very wide.
The safety of Lf(1–11) was investigated during the first three trials conducted in humans using
ascending doses of the peptide. The investigation was done in healthy volunteers and to patients
receiving autologous haematopoietic stem-cell transplantation following conditioning with high-dose
melphalan for multiple myeloma or lymphoplasmocytic lymphoma. Intravenous doses of up to 5 mg
daily for 5 days showed a very favourable side-effect profile. The only undesirable effect was an
elevation of transaminases, which may be due to hLf(1–11), although current data does not allow any
cause-effect relationship to be postulated [61].
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The safety and tolerability of hLF(1–11) is under investigation in some clinical studies, sponsored
by AM-Pharma, but currently no other recruiting studies are on-going (from www.clinicaltrials.org
database) thus the future of pharmaceutical applications appears unclear.
4. Lf-Derived Peptides: Lactoferricin
After Lf proteolysis by pepsin under acidic conditions, a 25-residue peptide (Lf amino acid
residues 17–41) lactoferricin (Lfcin) was identified [62] The peptide has an abundance of basic amino
acids including lysine and arginine, as well as hydrophobic residues like tryptophan and phenylalanine.
In all Lfcins (derived from different mammalian species) a loop region with an intramolecular disulfide
bridge is present (milkAMP database id = LFB0084) (Figure 3) [62]. Table 2 shows the structure of
Lfcin of different origins [63]. The current hLfcin sequence contains this loop, but in this case a second
disulfide bond extends the overall structure, which is about twice as long as bLfcin. hLfcin is composed
of two fragments corresponding to 1–11 and 12–47 connected by a disulfide bridge [62,64] (milkAMP
database id = LFH0009).
Molecules 2016, 21, 752 6 of 23 
 
disulfide bridge is present (milkAMP database id = LFB0084) (Figure 3) [62]. Table 2 shows the 
structure of Lfcin of different origins [63]. The current hLfcin sequence contains this loop, but in this 
case a second disulfide bond extends the overall structure, which is about twice as long as bLfcin. 
hLfcin is composed of two fragments corresponding to 1–11 and 12–47 connected by a disulfide 
bridge [62,64] (milkAMP database id = LFH0009).  
 
Figure 3. Structure of Lfcin peptide. 
Table 2. Comparison of aminoacidic sequences of Lfcin from Lf of different mammalian species. 
Species Sequence
Human TKCFQWQRNMRKVRGPPVSCIKRDS 
Cow FKCRRWQWRMKKLGAPSITCVRRAF 
Buffalo LKCHRWQWRMKKLGAPSITCVRRAF 
Horse AKCAKFQRNMKKVRGPSVSCIRKTS  
Goat SKCYQWQRRMRKLGAPSITCVRRTS 
Camel KKCAQWQRRMKKVRGPSVTCVKKTS 
Mouse EKCLRWQNEMRKVGGPPLSCVKKSS 
For the different amino acids, the colours indicate: blue = positively charged (R, K, H); black = 
negatively charged (D, E); red = hydrophobic (I, L, V, A, P, M F, Y, W); green = hydrophilic (S, T, E, Q, 
N, C and G). 
Both bLfcin and hLfcin exist as an amphipathic α-helix in Lf but, after pepsin digestion, the former 
is transformed into amphipathic β-sheet hairpin in an aqueous environment, whereas the latter (bulkier 
model) also possess a parallel β-sheet that is lost after digestion, preserving the α-helix [64]. The retention 
of the α-helical region in hLfcin may be directly related to the additional length of the peptide. The 
ability of Lfcin to form amphipathic structures with net hydrophobic and positively-charged faces 
(Table 2) is a trait shared with other peptides having antimicrobial activity [65]. 
4.1. In Vitro Antibacterial and Anti-Fungal Activity 
The first study, in 1992, on Lfcin as an AMP reported it to be a more potent antibacterial and 
anti-fungal agent than intact Lf; it was shown to cause a rapid loss of colony-forming capacity in 
most of its targets [66]. Comparing the activity of Lfcin from different species (cow, mouse and goat) 
showed that bLfcin was the most potent [63]. For example, the MIC of bLfcin against certain E. coli 
strains was found to be around 30 µg/mL whereas a MIC of with 100 µg/mL was detected for hLfcin. 
bLfcin showed bactericidal activity against a range of Gram-positive and Gram-negative bacteria [67], 
whereas hLfcin only exerted bacteriostatic activity [62]. The wide range of activities are shown in 
Figure 3. Structure of Lfcin peptide.
Table 2. Comparison of aminoacidic sequences of Lfcin from Lf of different mammalian species.
Species Sequence
Human TKCFQWQRNMRKVRGPPVSCIKRDS
Cow FKCRRWQWRMKKLGAPSITCVRRAF
Buffalo LKCHRWQWRMKKLGAPSITCVRRAF
Horse AKCAKFQRNMKKVRGPSVSCIRKTS
Goat SKCYQWQRRMRKLGAPSITCVRRTS
Camel KKCAQWQRRMKKVRGPSVTCVKKTS
Mouse EKCLRWQNEMRKVGGPPLSCVKKSS
For the different amino acids, the colours indicate: blue = positively charged (R, K, H); black = negatively
charged (D, E); red = hydrophobic (I, L, V, A, P, M F, Y, W); green = hydrophilic (S, T, E, Q, N, C and G).
Both bLfcin and hLfcin exist as an am h p thic α-helix in Lf but, aft r pepsin digestion, the
former is transformed into amphipathic β-sheet hairpin in an aqueous environment, whereas the
latter (bulkier model) also possess a parallel β-sheet that is lost after digestion, preserving the
α-helix [64]. The retention of the α-helical region in hLfcin may be directly related to the additional
length of the peptide. The ability of Lfcin to form amphipathic structures with net hydrophobic and
positively-charged faces (T ble 2) is a trait shared with other peptides having antimicrobial activity [65].
Molecules 2016, 21, 752 7 of 25
4.1. In Vitro Antibacterial and Anti-Fungal Activity
The first study, in 1992, on Lfcin as an AMP reported it to be a more potent antibacterial and
anti-fungal agent than intact Lf; it was shown to cause a rapid loss of colony-forming capacity in
most of its targets [66]. Comparing the activity of Lfcin from different species (cow, mouse and
goat) showed that bLfcin was the most potent [63]. For example, the MIC of bLfcin against certain
E. coli strains was found to be around 30 µg/mL whereas a MIC of with 100 µg/mL was detected
for hLfcin. bLfcin showed bactericidal activity against a range of Gram-positive and Gram-negative
bacteria [67], whereas hLfcin only exerted bacteriostatic activity [62]. The wide range of activities are
shown in Table 3; the MIC as antibacterial, antifungal and anti-protozoarian activities are taken from
the milkAMP database [14].
Very recently, data have been reported on Lfcin and other Lf peptides derived from Lf active
against Mycobacterium avium [68]. Both human and bovine Lfcins, as well as Lf(1–11), were active
against M. avium strains of different virulence, the bovine peptide being more active than its human
counterpart. However, some strains, such as Pseudomonas fluorescens, Enterococcus faecalis, and
Bifidobacterium bifidum, were found to be resistant to Lfcin [69].
The antibacterial activity of Lfcin is thought to involve the disordering and alteration of the
permeability of the bacterial membrane, resulting in inhibition of macromolecular biosynthesis and
ultimately cell death [70]. In terms of the structure-activity relationship, the mechanism of action of
Lfcin has been attributed to the 11-amino-acid amphipathic α-helical region [71], and the importance
of the initial electrostatic interaction is highlighted by the high overall positive charge of these peptides;
a net charge of at least +4 is necessary for optimal antibacterial activity [72]. This is confirmed by the
fact that murine Lfcin (mLfcin), which contains two glutamine residues, lacks antibacterial activity
(Table 2) [63] and also by the increased activity of C-terminally amidated undecapeptides derived from
various Lfcins [72]. Since arginine can interact both electrostatically and through multiple hydrogen
bonds with the negatively-charged surface of bacteria, it is thought that this amino acid is the most
effective for targeting the peptide to the bacterial membrane. In addition, the guanidinium group
adds bulk to the side chain, thereby potentially contributing to membrane disruption [71]. Once the
positively charged residues bring Lfcin into contact with the bacterial cell, the hydrophobic residues
(in particular tryptophan) interact with the lipophilic portion of the membrane, becoming embedded
in its surface and destabilizing the packing of the phospholipids. At least two tryptophan residues
(the best value being with three residues) are required to ensure a maximal thinning of the membrane
in a certain radius around the peptide [73].
On Gram-negative bacteria, antimicrobial peptides act on lipopolysaccharides, whereas on
Gram-positive bacteria Lfcin acts on lipoteichoic and teichoic acids. Studies have indicated that
bLfcin leads to depolarization of the cell membrane without causing the lysis of the cells [70], that it
exerts its bactericidal effect initially by acting on the bacterial cell surface, and subsequently on the
cytoplasmic contents [74].
The role of disulfide is not yet fully understood, and Liu et al. [74] recently failed to find a
significant difference in MICs between the disulfide-bridged peptide and its linear counterpart, while
another study showed three-times-higher activity for the disulfide-bridged peptide [63]. Intracellular
targets, such as phosphoenolpyruvate carboxylase, were detected using E. coli proteome chips,
indicating that one of Lfcin’s mechanisms of action may be associated with pyruvate metabolism [75].
Furthermore, bLfcin inhibits phosphorylation of the response regulators and of the two-component
system’s (TCSs) cognate sensor kinases. The role of the TCS is to protect the integrity of bacterial cell
membranes against antimicrobial peptides [76]. However, the homologous examination of response
regulators and sensor kinases in probiotics, including Bifidobacterium and Lactobacillus, showed that
this motif was not present, suggesting that bLfcin may have only marginal effects on the microbioma
probiotics in the intestine [76].
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Table 3. Activities of bLfcin against different bacterial, fungal and parasite species. References from [14].
Gram Positive MIC (µg/mL) Gram Negative MIC (µg/mL)
Bacillus subtilis ATCC 6633 0.6–2 Escherichia coli IID-861 6–50
B. subtilis 2116 7.8 E. coli ATCC 25922 3.3–30
B. subtilis IFO-3009 2 E. coli O111 6–12
B. cereus MMI-272 9 E. coli O157:H7-A 8
B. cereus 6349 15.6 E. coli O157:H7-B 8
B. circulans JCM-2504T 0.6 E. coli O157:H7-C 10
B. sphaericus 7585 1.9 E. coli O157:H7-D 8
Staphylococcus aureus JCM-2151 6-25 E. coli O157 wild type 7.8
S. aureus JCM-2179 6 E. coli CL99 1–2 4
S. aureus JCM-2413 18 E. coli K12 UB1005 1.6
S. aureus ATCC 25923 30 E. coli K12 UB1005 DC-2 1.6
S. aureus ATCC 29213 6.6 E. coli 7275 7.8
S. aureus 8530 15.6 E. coli 10418 3.9
S. aureus 8532 15.6 E. coli wild type 15.6–31.2
S. aureus R1 (antib-res) 12 Pseudomonas aeruginosa MMI-603 12–24
S. epidermidis JCM-2414T 3–6 P. aeruginosa IFO-3445 12–18
S. epidermidis 4276 7.8 P. aeruginosa IFO-3446 24
S. haemolyticus JCM-2416T 1 P. aeruginosa IFO-3448 45
S. hominus JCM-2419T 3 P. aeruginosa IFO-3452 30
S. sp. wild type 7.8–15.6 P. aeruginosa ATCC-2783 3.3
Listeria monocytogenes IDF-Ib 0.6 P. aeruginosa PAO 3.3
L. monocytogenes JCM-7673 1 P. aeruginosa 10662 31.2
L. monocytogenes JCM-7674 3 P. aeruginosa wild type 15.6–31.2
L. monocytogenes EGD 1.6 P. putida wild type 15.6
L. monocytogenes 4b 6.6 P. cepacia wild type 250–500
L. monocytogenes 5105 1.9 P. fluorescens wild type 15.6
Streptococcus bovis JCM-5672 3–6 Pseudomonas fluorescens IFO-14160 >60
S. mutans JCM-5705T 6 Salmonella enteritidis IID-604 12–18
S. mutans JCM-5175 6 S. typhimurium SH7641 1.6
S. mutans JCM-5176 3 S. typhimurium SL696 5
S. thermophilus ATCC-19258 3 S. typhimurium 6749 1.6
S. lactis ATCC-19435 3 S.montevideo SL5222 3
S. cremoris ATCC-9265 3 S. newport 5751 7.8
Lactobacillus. casei MMI-114 12 S. typhi wild type 7.8–15.6
Corynebacterium ammoniagenes JCM-1306 0.3 S. enteritidis wild type 7.8
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Table 3. Cont.
Gram Positive MIC (µg/mL) Gram Negative MIC (µg/mL)
C. renale JCM-1322 1 Yersinia enterocolitica IID-981 6–24
C. diphtheriae JCM-1310 18 Y. enterocolitica wild type 62.5
Clostridium perfringens ATCC-6013 24 Proteus vulgaris JCM 1668T 12–45
C. paraputrificum MMI-25 3 P. vulgaris wild type 500
Micrococcus sp. wild type 7.8–31.2 P. vulgaris 4635 500
Bifidobacterium adolescentis ATCC-15703 no P. mirabilis wild type 250–500
B. breve ATCC-15700 no P. mirabilis NCTC-60 >200
B. longum ATCG15707 no P. mirabilis ATCC 35659 >1000
B. infantis ATCC-15697 no P. rettgeri wild type 250
B. bifidum ATCC-15696 >60 ˆ 103 P. sp. wild type 500
Klebsiella pneumoniae 418 500 Klebsiella pneumoniae JCM 1662T 9
Enterococcus faecalis ATCCE 19433 >60 K. pneumoniae JCM-16623 12
Enterococcus sp. wild type 62.5–125 K. pneumoniae 5055 15.6
K. pneumoniae wild type 15.6–62.5
K. pneumoniae 418 500
Shigella flexneri 5452 3.9
Shigella flexneri wild type 3.9
Shigella sonnei wild type 7.8
Enterobacter intermedius wild type 15.6
Enterobacter aerogenes wild type 125
Enterobacter cloacae wild type 70.3
Enterobacter sp. wild type 7.8
Serratia sp. wild type 500
S. marcescens wild type 500
S. liquefaciens wild type 500
Citrobacter freundii wild type 7.8–62.5
C. diversus wild type 62.5
Bacteroides distasonis MMI-M602 no
B. vulgatus MMI-S601 no
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Yeast MIC (µg/mL) Filamentous Fungi MIC (µg/mL)
Candida. albicans TIMM 0154 25 Trichophyton mentagrophytes TIMM 1189 12
Candida albicans TIMM 1768 12.5–400 T. mentagrophytes TIMM 2789 6.3
C. albicans TIMM 3164 400 T. mentagrophytes IFO 5466 30
C. albicans TIMM 3315 50 T. mentagrophytes IFO 5812 30
C. albicans TIMM 3317 200 T. mentagrophytes IFO 5974 45
C. albicans JCM1542T 24 T. mentagrophytes 5
C. albicans JCM2072 30 T. rubrum IFO 6203 24
C. albicans JCM2075 45 T. rubrum IFO 32409 13
C. albicans JCM2076 24 T. tonsurans 5–40
C. albicans JCM2374 24 T. violaceum 40
C. albicans JCM2900 24 T. rubrum >80
C. albicans JCM2901 45 T. shoenleinii >80
C. albicans JCM2902 60 Nannizzia incurvata JCM 1906 18
C. albicans JCM2904 45 N. otae JCM 1909 60
C. albicans 6372 0.8 N. gypsea JCM 1903 >60
C. albicans 6434 0.8 Penicillium pinophilum JCM 5593 45
C. albicans ATCC 90028 400 P. vermiculatum JCM 5595 45
C. albicans wild type 7.8–21.67 P. notatum >80
C. parapsilosis wild type 7.8–80 P. expansum >80
C. tropicalis 0.31–1.25 Aspergillus versicolor 10
C. glabrata 120 A. fumigatus JCM 1917 >60
C. guilliermondii A. niger JCM 5546 >60
C. kefyr 2.5–10 A. fumigatus >80
C. krusei 10–20 A. niger >80
Cryptococcus uniguttulatus JCM 3685 6 A. flavus >80
C. curvatus JCM 1532T 9 A. clavatus >80
C. albidus JCM 8252 24 Fusarium moniliforme 2.5–5
C. neoformans 0.63 Absidia corymbifera 40
Trichosporon cutaneum JCM 2466 18 Microsporum canis 40
T. cutaneum 1.25–2.5 M. gypseum 20–40
Saccharomyces cerevisiae 0.63 Epidermophyton floccosum 0.31-2.5
Fonsecaea pedrosoi 5
Exophiala dermatitidis 2
Phialophora verrucosa 5–10
Cladosporium trichoides 0.63–1.2
Paracoccidioides brasiliensis 5
Sporothrix schenckii 2–10
Rhizopus oryzae JCM 5557 >60
Mucor circinelloides >80
M. racemosus >80
Parasite LD50 (µM)
Giardia lamblia 2.8
Entamoeba histolytica 647
Toxoplasma gondii no
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In addition to antimicrobial properties, Lfcin of human and bovine origin has also been found to
be effective in inhibiting the classical complement pathway. Both Lf and Lfcin increase interleukin-8
release from polymorphonucleate leukocytes, suggesting their immunomodulatory function [77].
This implies a role of these peptides in suppressing the inflammatory effects caused by bacteria [78].
Lfcin was found to be produced in the human stomach, indicating that this peptide is generated in vivo
for host defense [79].
In regard to its toxicity on eukaryotic cells, measured as haemolytic activity, bLfcin displayed
slight hemolytic activity at a concentration of 64 µg/mL, exhibiting a marked antimicrobial activity
against most of the test bacteria [74]. However, a study of the relationship between structure and
activity found that the undecapeptide structure is essentially non-haemolytic, but that undecapeptides
containing more than three tryptophan residues produced 50% haemolysis of human red blood
cells at concentrations above 400 µg/mL (>230 µM) [72]. Toxicity seems also related to increased
hydrophobicity. In a strategy to improve antimicrobial activity of Lfcin peptides were linked by
N-acylation to hydrophobic chains. The derivatives resulted in higher antibacterial activity but also in
higher toxicity towards eukaryotic cells [80,81].
Apart from having a broad antibacterial spectrum, bLfcin was also found to be efficacious against
yeasts, such as Candida albicans, Cryptococcus uniguttulatus, C. curvatus, C. albidus and Trichosporon
cutaneum [67,82] (see Table 3). The anti-fungal mechanism has not yet been fully clarified. bLfcin
interacts with and disrupts the integrity of the Candida spp. membrane within the range 18 to
60 µg/mL (MIC). Cells of nine different strains exposed to bLfcin exhibited severe ultra-structural
damage, reflecting the peptide’s induction of an autolytic response [83].
4.2. Synergy with Antibacterial and Anti-Fungal Drugs
Synergistic effects, deriving from the combination of active agents with different modes of action,
provide an attractive therapeutic option (see Table 4). The loss of inner membrane integrity may
promote the uptake of other agents, for example antibiotics or other antibacterial peptides, leading
to synergy with conventional antibiotics. In this respect, Lfcins also appear to affect the cytoplasm
physiology of fungal cells. In addition, some azole-resistant C. albicans strains are inhibited by
fluconazole or itraconazole to a greater extent in the presence of relatively low concentrations of
Lf or bLfcin. Conversely, no cooperative effect with non-azole types of antifungal agents, such as
amphotericin B or 5-flucytosine, was observed. These findings indicate that LF or bLFcin may play a
valuable role in inhibiting the mycelial form of azole-resistant C. albicans [52,84].
Table 4. Synergistic effects of Lf AMPs [13].
Lf
Peptide Drug
Bacterial, Fungal,
Parasite Species Refs
Lf(1–11) Fluconazole Candida sp. [53]
bLfcin Clotrimazole, ketoconazole, itraconazole, fluconazole C. albicans [52]
Cecropin A, aureomycin E. coli [74]
Aureomycin S. aureus [74]
Fluconazole, itraconazole C. albicans [84]
Erythromycin E. coli [85]
Ciprofloxacin, ceftazidime, gentamicin S. aureus, E. coli [86]
Ciprofloxacin, norfloxacin E. coli [87]
Minocycline, acid cholic, cysteine, various acylglycerols,
β-cyclodextrin S. aureus [88]
Metronidazole Entamoeba histolytica [89]
Nisin, Lf E. coli, S. epidermidis [90]
Lfampin Ampicillin S. aureus [91]
Based on Lfcin’s high antibacterial and antifungal activity, in order to identify possible synergic
therapeutic strategies, Lf peptides have been tested in association with drugs. Following initial
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evaluations, Vorland et al. examined whether bLfcin interfered with the action of various antibiotics
against E. coli and S. aureus [85]. For what regards E. coli, marked synergism was observed with
erythromycin, partial synergism with penicillin G, vancomycin, and gentamicin, whereas there was
no effect with cycloserine or colistin. As far as S. aureus is concerned, only penicillin G acted in
partial synergism with bLfcin, whereas bLfcin antagonized vancomycin and gentamicin also at low
concentrations. The difference in activity is related to the different mechanisms of action of antibiotics
on both the membranes and the intracellular targets. In some cases, however, bLfcin may facilitate the
uptake of antibiotics across the cell envelope.
Longhi et al. analysed the susceptibility to fluoroquinolones of uropathogenic E. coli strains, and
the influence of bLfcin on the activity of norfloxacin and ciprofloxacin against these strains [87]. The
research revealed synergistic, partial synergistic, or indifferent effects depending on the tested E. coli
strains. Furthermore these results demonstrated that the association of fluoroquinolones with bLfcin
could allow the use of these therapeutic agents at lower concentrations for a reasonable number of
E. coli strains.
Liu et al. found a synergistic effect between bLfcin and aureomycin and cecropin A, on E. coli. No
synergy, but rather independent action, was found in all bacteria tested when combining bLfcin and
neomycin. No antagonism was observed between the antibacterial agents used and bLfcin against
E. coli, S. aureus and P. aeruginosa. The MICs for the antibiotics markedly decreased when the peptide
was added, as expected, indicating that bLfcin might act in combination with these antimicrobial
agents against E. coli, S. aureus and P. aeruginosa [74].
Wakabayashi investigated the effects of bLfcin combined with antibiotics or various
other compounds against S. aureus [88]. Among conventional antibiotics, minocycline
increased the bactericidal activity of bLfcin against S. aureus, but methicillin, ceftizoxime, and
sulfamethoxazole-trimethoprim did not have such an effect. The combination of minocycline
and bLfcin had synergistic effects against three antibiotic-resistant strains of S. aureus. Further,
33 compounds were screened, including acids and salts, alcohols, sugars, lipids, amino acids,
proteins and peptides, were tested in combination with bLfcin and among these medium-chain
(8, 12, 14 carbons) monoacylglycerols increased the bactericidal activity of bLfcin against three
S. aureus strains.
A cooperative action of milk proteins was investigated by Lopez-Esposito [90]. In this study
Lf, bLfcin, and alphaS2-casein were assayed against E. coli, S. epidermidis, Listeria monocytogenes
and Salmonella cholerae-suis, in combination with nisin. This bacteriocin produced by
Lactocococcus lactis spp. lactis is primarily active against Gram-positive bacteria, and has found practical
application as a food preservative. The synergy was observed for the combination Lf and bLfcin
against E. coli and S. epidermidis. When bLfcin was combined with nisin, an antagonistic effect was
found against E. coli, whereas the synergy index achieved against S. epidermidis revealed an additive
interaction. Murata et al. [92] subsequently identified a milk RNAse protein (15 kDa) able to double or
quadruple the antimicrobial activity of bovine Lf and LFcin against G-negative and positive bacteria.
4.3. Anti-Parasitic Activities of Lfcin
A synergistic effect against Entamoeba histolytica, was found by Leon-Sicairos et al. between
metronidazole and Lf or bLfcin: in the presence of 31 µM of Lf or 323 µM of bLfcin, approximately
one-third to one-fifth of the full metronidazole concentration effectively killed the majority of amoebas.
This result opens promising perspectives for reducing the dose of antiamoebic drug in patients [89].
The ascertained giardicidal activity of bLf has the limit to be hampered by metal ions. It has been
demonstrated that the most efficient activity against Giardia, is due to bLfcin. The latter also has the
advantage, as compared to bLf to be insensitive to the inhibiting action of metals, except for Fe3+ [93].
The study authors opined that, as the intestinal lumen has little free iron, it is likely that Lf-derived
peptides remain active within the human small intestine.
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Treatment of Toxoplasma gondii with bLfcin leads to inactivation of the parasite’s ability to penetrate
the host cell [94]. This protective effect in mice was confirmed by Isamida et al. [95] using oral
or i.p. administration of the peptide (5 mg and 0.1 mg respectively). Subsequently, Omata et al.
observed that sporozoites of T. gondii and Eimeria stiedai pre-incubated with Lfcin showed decreased
penetration activity of mouse embryonal cells; mice inoculated with 105 sporozoites preincubated
with Lfcin showed a higher survival rate than those inoculated with the same number of untreated
sporozoites [18].
4.4. Preclinical and Clinical Trials of Lfcin
On the basis of in vitro data confirming bLfcin as the best performing peptide, with broad-range
activities and low MIC values, several preclinical trials were run; the principal results are reported
below, classified by disease treated or by administration route.
4.4.1. Ocular Infections
Recently, Oo et al. [86] reported that two antibiotics (ciprofloxacin and ceftazidime) act
synergistically with bLfcin against various strains of P. aeruginosa isolated from corneal infections
in vitro. In mouse corneas, the addition of bLfcin as adjuvant enhanced the activity of ciprofloxacin,
with 1.5 log reduction of bacterial growth compared with negative control, although the peptide alone
had no significant effect. Moreover, bLfcin with or without ciprofloxacin appeared able to reduce
myeloperoxidase activity and consequently host inflammatory response in vivo.
More recently, an ex vivo study on the efficacy of the combination of bLfcin with other antifungal
agents was performed. The aim was to assess the performance of such a combination in the inhibition
of evaluated of biofilm formation of three fungal strains, Aspergillus fumigatus, Fusarium solani, and
Candida albicans, isolated from patients with keratitis [96]. Biofilm eradication is now a major challenge,
to overcome the incidence of drug resistance in keratitis treatment. This disease constitutes one of
the most important causes of ocular morbidity and sight loss in developing nations, as well as in
contact lens users, as reported in recent epidemics of Fusarium spp. keratitis. bLfcin, in combination
with antifungal agents, increased the susceptibility to fluconazole, voriconazole, and amphotericin
B and, when added to a lens-care solution, drastically reduced the mature biofilm on contact lenses.
This finding suggested that bLfcin might be a promising candidate for clinical use in improving the
susceptibility of biofilm to antifungals, and could also be used as an antibiofilm-antifungal additive in
lens-care solutions.
4.4.2. Osteo-Articular Diseases
In addition to antibacterial and antifungal uses, bLfcin’s anti-catabolic and anti-inflammatory
effects were recently assessed in ex vivo experiments on human articular cartilage and synovium [97].
bLfcin demonstrated chondroprotective properties, damping the inflammatory response in synovial
fibroblasts, and may thus be seen as a promising molecule in the prevention and/or treatment of
degenerative joint diseases. Additionally, considering its antimicrobial activities, bLfcin may also bring
therapeutic benefits to septic arthritis.
4.4.3. Gastro-Intestinal Diseases
The first reports of the bacteriostatic effects of Lf and Lf pepsine-hydrolysate (LFH) after
per os administration, concerned Enterobacteriaceae in the gut environment [98], The same author
demonstrated the efficacy of bLf and LFH to control and limit the growth of different strains of
Clostridium spp. in a mouse model [99].
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4.4.4. Dermatological Diseases
Lf and bLfcin have been tested as possible therapeutic agents for the treatment of dermatophytosis,
one of the most common infectious diseases of the stratum corneum. The in vitro MIC of Lf and Lfcin
against Trichophyton spp. demonstrated a great variability, depending on the strain tested and medium
used, in contrast of what observed with the antifungal drug griseofulvin which gave constant and
reproducible results. The efficacy of oral Lf administration was assessed on guinea pigs experimentally
infected with Tinea corporis and T. pedis. The study authors assumed that Lf did not have any direct
antifungal activity, but that it enhanced the inflammatory response involving cell-mediated immunity
required for the cure of dermatophytosis [100].
4.5. Veterinary Applications
Mastitis is one of the most significant and costly diseases in dairy cattle. It is an intramammary
bacterial infections caused by several bacteria, with S. aureus, Streptococcus uberis, and Streptococcus
dysgalactiae being the most frequently involved pathogens. Intramammary treatment with Lf was not
satisfactory for overcoming beta-lactam resistant S. aureus infection. However, Lf co-administered
with penicillin G increased the cure rate (from 12.5% to 33%), reducing beta-lactamase activity in
resistant S. aureus strains [101]. The strong activity against mastitis pathogens of AMP and bLfcin, in
particular, has spurred interest in their potential application to the control of udder infections. In an
in vivo trial, Kawai et al. tested an infusion of LFH in cows affected by subclinical mastitis, caused by
various bacteria, including E. coli and staphylococci [102]. The results showed a significant reduction of
bacteria in the mammary tissue already on day one after infusion, and eradication of the disease after
14 days. Recently, bLfcin exhibited in vitro biocidal activity against both the algae Prototheca zopfii, the
causative agent of protothecal mastitis, and several yeasts causing fungal mastitis isolated from clinical
cases of bovine mastitis However these promising in vitro findings must be confirmed in vivo [103].
In a different approach, bLfcin was expressed in goat mammary gland, using a plasmid vector as
preventive therapy [104]. The results confirmed the persistence of the peptide in goat’s milk for 6 days
after injection of the recombinant plasmid, but with variations in the concentration after 3 days. Milk
produced during this period was active in vitro against S. aureus ATCC 25923 and E. coli D12K31.
hLf and Lfcin have also been studied as components of dietary supplementation in livestock,
and particularly in pigs. Tang et al. analysed the role of Lfcin to replace colistin sulphate in a study
on piglets weaned at 21 days of age and challenged with enterotoxigenic E. coli, that examined gut
microflora, circulating cytokines, and intestinal mucosal morphology [105]. When cipB-Lfcin, a fusion
protein that releases Lfcin in the animal stomach, was given as a dietary supplement at the dose
of 100 mg/kg, the development of villus-crypt architecture of the intestinal mucosa was observed.
Because Lfcin can decrease the concentration of E. coli and keep the gut tissue healthy, pigs fed with
cipB-Lfcin had lower serum levels of circulating cytokines than pigs fed a standard or control diet [95].
Further studies of the use of these peptides as an alternative to antimicrobial growth promoters in pig
production comprised construct cipB-Lfcin-Lframpin [106]. Piglets fed with construct (100 mg/kg) or
control diets were challenged with enterotoxigenic E. coli. The AMP diet enhanced growth performance
to a similar extent as did colistin sulphate. Analogous results were obtained using fusion protein
containing bLfcin or Lfampin produced by a recombinant of the yeast Pichia pastoris [107,108].
A further study investigated the effects of bLfcin on performance, faecal score, and dry matter of
weaned piglets orally challenged with enterotoxigenic E. coli F4, confirming bLfcin’s activity combined
with its absence of toxicity [109].
Recently, an in vivo study comprised treating dogs affected by external otitis with bacterial and
yeast overgrowth, using an emulsion containing bLfcin, verbascoside and glycerophosphoinositol
lysine [110]. After 7 days’ treatment, there was a significant decrease in microbial overgrowth, together
with a clinical improvement in the otitis, suggesting the therapeutic combination possessed synergistic
antibacterial and antifungal activity. An in vitro study in the present authors’ laboratory confirmed the
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anti-fungal activity of bLfcin against Malassezia spp. isolated from dogs or cats affected by fungal otitis
(unpublished data).
4.6. Lfcin for Food Applications
On the basis of its wide spectrum of activity, bLfcin is also a promising candidate as preservative
in various foods and beverages. The main applications of AMP are well summarized in a recent
review [13]. Chiefly considering bLfcin and LFH, the principal studies examined were as follows:
4.6.1. Dairy products
Quintieri and co-workers [111] evaluated the effect of bLfcin to control spoilage by mesophilic
bacteria in Mozzarella cheese and, more recently, that of LFH in controlling P. fluorescens, responsible for
cheese pigmentation in high-moisture Mozzarella cheese. LFH (rich in bLfcin) efficiently counteracted
the chromatic spoilage of cheese throughout the storage time [112]. The inclusion of LFH in the holding
liquid did not significantly affect the viable cell counts of useful microorganisms; however, resistance of
AMPs to proteases becomes a major concern, because they rapidly degrade in food matrices, especially
those containing lactic acid bacteria whose proteolytic attitude is very strong. This aspect strongly
limits their action time. For example, bLfcin was reported to have a short half-life in contact with food
microbial communities [111,112]. For these reasons, bLfcin resistance to microbial proteolysis was also
assessed using different strains of yogurt starter (Streptococcus thermophilus and Lactobacillus delbrueckii
sp. bulgaricus strains). However in acidic conditions (pH 4.5) the bLfcin resistance to hydrolysis was
confirmed [113].
4.6.2. Oenological applications
Recently, the use of both bLf and bLfcin was examined, in a study that assessed their control over
food spoilage bacteria and yeasts. Enrique et al. [114] evaluated both in vitro, and subsequently in
micro-vinification experiments, the antimicrobial activity exerted by LFH and one synthetic peptide
derived from bLf (bLfcin17e31) against wine-related Gram-positive spoilage bacteria. The study
authors demonstrated the additional killing effect of bLfcin17e31 on bacterial cells belonging to
Pediococcus damnosus and Oenococcus oeni, already stressed by changes in chemical composition of the
must caused by Saccharomyces cerevisiae fermentation.
4.6.3. Fruits and vegetables
Recently, both bLf and bLfcin were investigated for their potential in controlling spoilage
pathogens in fruits and vegetables. Tests carried out on mandarins with bLfcin and Lf (17–31) showed a
significant protection against Penicillium digitatum at a concentration close to the in vitro MIC value [115].
More recently Baruzzi et al. demonstrated the interesting activity of bLfcin in controlling microbial
spoilage in ready-to-eat leafy vegetables during cold storage [116]. These studies introduce alternative
approaches to fungicides in fruit and vegetable production.
4.6.4. Meat products
bLfcin is currently also being assessed to control food-borne pathogens in meat matrices. Initial
studies on the addition of bLfcin to ground meat inoculated with enterohemorrhagic E. coli O157:H7
did not significantly reduce the bacterial population [117], although LFH exerted antimicrobial action
on this strain in controlled experiments [118]. Similar results were obtained on beef plates and adipose
tissue after treatment by immersion in a solution of 10 µg/mL of bLfcin [119]. The possibility of
combining LfcinB and high pressure to reduce colonization of chicken fillets preinoculated with
Pseudomonas fluorescens ATCC948, Listeria monocytogenes CECT5725 and E. coli O157:H7 strain CECT
4972 was evaluated, although if failed to produce a relevant reduction [120,121]. In another approach,
LFH was applied to ground beef and meat fractions [122]. In conclusion of this chapter it is worth
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highlighting that the strategy of employing milk-derived AMPs to control spoilage bacteria and
food-borne infections not only satisfies the need to reduce the use of antibiotics and food preservatives
but also allows to reduce the use of salt and sugars with benefits for consumer’s health.
5. Lf Derived Peptides: Lactoferrampin
Lactoferrampin (Lfampin) has recently been identified as being of potential interest by sequence
scanning, based on the common feature of antimicrobial peptides: a highly positive charge, a
hydrophobic domain and hence an amphipathic character (Figure 4).
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Figure 4. Structure of Lfampin.
Lfampin comprises residues 268–284 in the N1 domain of Lf, and was found to be located in
close proximity to Lfcin. However, the bactericidal activity of LFampin differs from that of bLfcin,
although both peptides share amphipathic and cationic features; they have a markedly different
amino acid composition and chain length, and therefore their structures differ greatly. The sequence
comparison of Lfampin from six different species shows a uniform preponderance of cationic amino
acid residues among hydrophobic residues (Table 5). As an antimicrobial peptide Lfampin plays a
key role in membrane-mediated activities of Lf [123]. Following the initial discovery of LFampin
268–284 (produced by solid-phase chemistry), a slightly longer sequence (produced by action of a
single endopeptidase on bLf) was published that included an additional N-terminal helix cap region,
Asp-Leu-Ile. It was found that the longer peptide LFampin 265–284 had higher activity [123]. For both
peptides, the helical conformation was found to be critical for effectiveness against Gram-positive
bacteria [124].
Table 5. Comparison of amino acid sequences of Lfampin from Lf from six s ecies.
Species Sequence
Human WNLLRQAQEKFGKDKSP
Cow WKLLSKAQEKFGKNKSR
Buffalo WKLLSKAQEKFGKNKSG
Horse WKLLHRAQEEFGRNKSS
Goat WELLRKAQEKFGKNKSQ
Camel WKLLVKAQEKFGRGKPS
For the different amino acids, the colours indicate: blue = positively charged (R, K, H); black = negatively
charged (D, E); red = hydrophobic (I, L, V, A, P, M F, Y, W); green = hydrophilic (S, T, E, Q, N, C and G).
The sequence comparison of Lfampin from six different species shows a uniform preponderance
of positively-charged residues among the hydrophobic domain containing tryptophan, a residue that
is involved in membrane insertion.
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Lfampin exhibits broad antimicrobial action against several Gram-positive and Gram-negative
bacteria, yeast and parasites: data taken from the MilkAMP database are reported in Table 6 [14,123].
Table 6. Activities of Lfampin 265–284 and 268–285 [14].
Gram-Positive LC50 (µM) Gram-Negative LC50 (µM) Yeast LC50 (µM)
Streptococcus sanguis SK4 4.8 E. coli K12 5.8 Candida albicans 315ATCC 10231 0.7–2.1
Bacillus subtilis ATCC 9372 5.5–20 E. coli O157:H7 25
S. aureus MRSA 20 E. coli MREPEC 20 Parasite
Streptococcus mutans 5.5 E. coli EPECE2348/69 20 Leishmania donovani 25.3
Actinomyces naeslundii ATCC 12104 4.3 P. aeruginosa Pak 7
P. aeruginosa PAO 5.8–15
Although no advanced preclinical trials or applications have yet been reported, the study by
Flores et al. shows that the combination of ampicillin with LFcin 17–30 or LFampin 265–284 enhanced
the inhibitory effect on growth of S. aureus (99.9%) for both peptides, suggesting that a synergistic
effect occurs. These data strongly suggest that LFcin 17–30 and LFampin 265–284 act synergistically
with antibiotics against multi drug resistant S. aureus strains in vitro [91].
6. Conclusions
With the steady increase in the number of multidrug-resistant pathogens, many patients are
looking to alternative medicine instead of classical antibiotics and antimicrobial agents. It has thus
become necessary to explore natural resources for new, alternative and/or complementary medicines.
In this search for novel antimicrobial agents for the future, Lf, a multifunctional protein that participates
in a range of important physiological processes, offers a new source with potential pharmaceutical
applications. Moreover, Lf fragments or derivatives are still being explored, through both chemical
synthesis and tryptic digestion, as has recently been described [125].
The best demonstrated effects of Lf and Lf AMP in the treatment of various infectious diseases
caused by bacteria, fungi, and protozoa in humans and animals have been described; however,
considerable research remains to be done to achieve a better understanding of Lf and Lf-derived AMPs
activity. Actually, the functional peptides till now produced from Lf and studied, Lf(1–11), Lfcin and
LFampin, are still underexplored but promising results begin to be obtained suggesting new interesting
antimicrobial actions that can be exploited.
Lf(1–11) is active in vitro and in vivo against various bacteria and yeast although showing
few synergistic effects with antibiotics. Lfcin displays a higher efficacy potent as an antibacterial,
anti-fungal and antiparasitic agent than intact Lf, particularly in ocular infections, osteo-articular,
gastrointestinal and dermatological diseases. bLfcin is the most potent Lfcin, and is also used in
veterinary medicine. Bovine mastitis, intestinal infections in piglets, and canine dermatitis are the
most important in vivo applications.
Both bLf and bLfcin have recently been tested for food applications due to their significant
antibacterial and antifungal activities, combined with a wide safety profile. They find interesting
applications in food preservation from both spoilage and pathogenic bacteria and fungi. This strategy
may allow to reduce the use of chemical preservatives, reducing food loss due to spoilage, and lead to
the development of “novel” food products (with lower salt content, less acidic, etc.) able to satisfy the
demands of consumers and industry.
Further, the ascertained protective roles of bLfcin, which have been demonstrated against
pathogens, and inflammation, but also cancer, make the molecule a centerpiece for the development
and application of drug candidates and functional foods. Natural origin, safety, marked activity, and
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possible use on the industrial scale, are the main features that make Lfcin interesting and promising as
a therapeutic agent.
LFampin exhibits broad antimicrobial action against several gram-positive and gram-negative
bacteria, yeasts, and parasites, but no advanced preclinical trials or applications have been reported
to date.
On the other hand, the overall research in this field reveals some bottlenecks such as the synergy
between Lfcin-derived peptides and antibiotics, which is relevant, in vitro but still far from optimal for
in vivo therapeutic use [126,127]. Combinations of milk AMPs with a greater number of antimicrobials
have to be tested, as they provide new directions to control pathogens growth. Systematic evaluations
on in vivo models, selecting different pathogens, pathologies and administration routes should be
welcomed. Another important issue is the cell-penetrating potential of AMPs as vectors for intracellular
targets [128].
Because Lfcin and Lfampin are spatially close in location, a generation of chimera peptides
containing the same sequences has been produced. Recent studies have shown that chimera peptides
exert stronger antimicrobial activity, as well as antiparasitic activity [91,129–131]. The construction of
chimera peptides, based on the active regions of Lf, may be a promising approach possibly leading to
interesting and improved activity. Nevertheless, some shortcoming of such chimera might stem from
the difficulty of producing bulk quantities, not fully disclosed toxicity, and stability issues.
Furthermore, besides the molecules object of the present review report, research on different
proteolytic fractions of whey proteins (from different mammalian species) lead to continuous discovery
of new peptides possessing antimicrobial activities. Hence, the research on such molecules, the
evaluation of their spectrum of activities and their in vitro and in vivo synergy with conventional
therapeutics, represent the main goals for the future production of novel peptides.
In conclusion, in recent years, peptides have attracted increasing interest as a new therapeutic
approach. They play a key-role due to their wide availability and the broad spectrum of activities,
which control many biochemical processes. More than sixty peptide drugs have reached the market,
and several hundred new therapeutic peptides are now in preclinical and clinical development.
However, the possible ready enzymatic degradation and the low cellular uptake greatly restrict the
use of these compounds as pharmaceutical agents.
A key-factor for enhancing stability and cellular permeability is the application of rational design
to partially modify chemical and physical properties of peptides. The challenge is therefore to improve
biological and pharmacological activity by making appropriate structural modifications on functional
groups present in the amino acids of natural peptides. We believe that in the future, once these
transformations will be achieved, the new molecules would benefit of significant stability and cell
permeability, which combined with the high efficiency, specificity and security of the natural molecules
will ensure success of peptide drugs.
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